Scholarlink

<p>Myocarditis, an inflammatory heart disease, often leads to severe cardiac dysfunction, including dilated cardiomyopathy and sudden death. Current treatments for myocarditis remain limited, necessitating the exploration of new therapeutic approaches. Liraglutide, a glucagon-like peptide-1 receptor agonist widely used for type 2 diabetes and obesity, has shown anti-inflammatory effects in other cardiovascular diseases. In this study, we investigated liraglutide’s effects on autoimmune myocarditis. Our findings demonstrated that liraglutide significantly reduced myocarditis severity by lowering heart weight/body weight ratio, serum cardiac troponin T levels, cardiac fibrosis, and inflammatory infiltration. Echocardiography showed improved left ventricular function, while immunofluorescence and RT-qPCR analyses revealed decreased T-cell and macrophage infiltration and reduced expression of pro-inflammatory cytokines. RNA sequencing indicated that liraglutide modulates the NLRP3 inflammasome and NF-κB pathways. These results suggest that liraglutide has the potential to be a therapeutic agent for myocarditis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月26日

查看全文
  • Lijuan Zhang,
  • Lishuai Han,
  • Yang Lu,
  • Quanzhou Chen

摘要

Myocarditis, an inflammatory heart disease, often leads to severe cardiac dysfunction, including dilated cardiomyopathy and sudden death. Current treatments for myocarditis remain limited, necessitating the exploration of new therapeutic approaches. Liraglutide, a glucagon-like peptide-1 receptor agonist widely used for type 2 diabetes and obesity, has shown anti-inflammatory effects in other cardiovascular diseases. In this study, we investigated liraglutide’s effects on autoimmune myocarditis. Our findings demonstrated that liraglutide significantly reduced myocarditis severity by lowering heart weight/body weight ratio, serum cardiac troponin T levels, cardiac fibrosis, and inflammatory infiltration. Echocardiography showed improved left ventricular function, while immunofluorescence and RT-qPCR analyses revealed decreased T-cell and macrophage infiltration and reduced expression of pro-inflammatory cytokines. RNA sequencing indicated that liraglutide modulates the NLRP3 inflammasome and NF-κB pathways. These results suggest that liraglutide has the potential to be a therapeutic agent for myocarditis.